Stock listing

LS Exchange:A0F57T Daiichi Sankyo Company, Limited Aktie

German listing (LS Exchange) of Daiichi Sankyo Company, Limited · home listing Tokyo:4568

Follow Daiichi Sankyo Company, Limited into a list and get an email when it puts out news.

Daiichi Sankyo Company, Limited logo
Ticker
LS Exchange:A0F57T
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
LS Exchange
Currency
EUR

What changed lately

Calls

Replays

  • Daiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call

    Fri, Jul 31, 2026 · 4:30 AM ET

    Watch Transcript

  • Daiichi Sankyo (Tokyo:4568) Q4 2025 Earnings Call

    Mon, May 11, 2026 · 4:00 AM ET

    Watch Transcript

  • Daiichi Sankyo (Tokyo:4568) Q3 2025 Earnings Call

    Tue, Dec 30, 2025 · 1:00 AM ET

    Watch Transcript

Latest news

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Oct 2, 2026

Notice Regarding NTK’s Filing of Appeal in Damages Claim Against Daiichi Sankyo

Sep 27, 2026

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

Sep 25, 2026

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

Sep 18, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

Sep 13, 2026

Daiichi Sankyo Receives Favorable Judgment in Damage Claim Filed by NTK

Sep 10, 2026

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Sep 1, 2026

(Modification of Disclosed Matter) Notice Regarding Change in the Effective Date of the Absorption-type Merger of Daiichi Sankyo with Its Wholly Owned

Aug 28, 2026

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Aug 27, 2026

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

Aug 26, 2026

All Daiichi Sankyo Company, Limited news

Decks

Daiichi Sankyo Company, Limited on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
63 in the last 12 months · 98 in all · newest Oct 2, 2026 · oldest 2025
Calls
13 calls with a replay · 13 with a transcript · latest Jul 31, 2026
Decks
43 decks · latest Jul 31, 2026

Where Daiichi Sankyo Company, Limited is listed

ListingExchangeCountryCurrency
Tokyo:4568 第一三共 · Home listingTokyoJapanJPY
OTC:DSNKYOTCUnited StatesUSD
gettex:D4SgettexGermanyEUR
OTC:DSKYFOTCUnited StatesUSD
Tradegate:D4STradegateGermanyEUR
LS Exchange:A0F57T · This pageLS ExchangeGermanyEUR
BMV:4568NBMVMexicoMXN
Lang & Schwarz:A0F57TLang & SchwarzGermanyEUR
Frankfurt:D4SFrankfurtGermanyEUR
Dusseldorf:D4SDusseldorfGermanyEUR
Hanover:D4SHanoverGermanyEUR
BIVA:4568NBIVAMexicoMXN
Frankfurt:D4S0FrankfurtGermanyEUR
Hamburg:D4SHamburgGermanyEUR
Munich:D4SMunichGermanyEUR
Stuttgart:D4SStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Daiichi Sankyo Company, Limited.